{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T14:08:35Z","timestamp":1788876515937,"version":"build-2803163510"},"reference-count":59,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Transitioning from oral to long-acting injectable (LAI) antipsychotics may improve adherence and reduce healthcare resource utilization (HCRU) in patients living with bipolar I disorder (BP-I), with potentially greater improvements with LAIs with dosing intervals longer than 1 month. Aripiprazole monohydrate is available as LAI formulations administered once-monthly [aripiprazole once-monthly (AOM)] or once every 2 months (aripiprazole 2-month ready-to-use [Ari 2MRTU]). This pre-post analysis described adherence, HCRU, and costs over 6 months in adults diagnosed with BP-I who transitioned from oral antipsychotics or AOM to Ari 2MRTU.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective, noninterventional study used Kythera Labs United States closed claims to identify adults diagnosed with BP-I, commercially or Medicaid-insured, and who transitioned from oral antipsychotics or AOM to Ari 2MRTU from April 2023\u2013September 2024 (index date = Ari 2MRTU transition). Continuous enrollment for 12 months pre- and 6 months post-index was required. Study outcomes were compared 6 months prior to and following the index date.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among those who transitioned from oral antipsychotics to Ari 2MRTU (n = 371),mean proportion of days covered (PDC) increased from 0.60 to 0.76 (26.2% relative increase), mean medication possession ratio (MPR) increased from 0.67 to 0.85 (26.8% relative increase), and proportion of patients with MPR \u2265 0.8 increased from 41.2% to 72.0% (74.5% relative increase) (all\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.0001). Notable reductions in all-cause inpatient visits and length of stay (LOS) were observed, along with reductions in BP-I\u2013related LOS and emergency department (ED) visits. All-cause inpatient, ED, and total medical (inpatient, outpatient, ED) costs declined. Among those who transitioned from AOM to Ari 2MRTU (n = 1,096), mean PDC increased from 0.56 to 0.81 (45.3% relative increase), mean MPR increased from 0.62 to 0.89 (43.7% relative increase), and proportion of patients with MPR \u2265 0.8 increased from 51.2% to 79.0%) (54.4% relative increase) (all\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.0001). Inpatient visits (all-cause, BP-I\u2013related), and all-cause LOS decreased, along with all-cause ED and total medical costs.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Transitioning to Ari 2MRTU was associated with improved treatment adherence and reduced selected HCRU measures and total medical costs, supporting its value as a treatment option for BP-I.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpsyt.2026.1904737","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T13:22:50Z","timestamp":1788873770000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world adherence, healthcare resource utilization, and costs following a transition to aripiprazole once every 2 months among patients diagnosed with bipolar I disorder in the United States"],"prefix":"10.3389","volume":"17","author":[{"given":"Soma S.","family":"Nag","sequence":"first","affiliation":[{"name":"Otsuka Pharmaceutical Development & Commercialization Inc.","place":["Princeton, NJ, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Urganus","sequence":"additional","affiliation":[{"name":"Lundbeck LLC","place":["Deerfield, IL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karimah S.","family":"Bell Lynum","sequence":"additional","affiliation":[{"name":"Otsuka Pharmaceutical Development & Commercialization Inc.","place":["Princeton, NJ, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Norman","family":"Atkins","sequence":"additional","affiliation":[{"name":"Otsuka Pharmaceutical Development & Commercialization Inc.","place":["Princeton, NJ, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onur","family":"Baser","sequence":"additional","affiliation":[{"name":"Graduate School of Public Health, City University of New York (CUNY)","place":["New York, NY, United States"]},{"name":"Columbia Data Analytics","place":["New York, NY, United States"]},{"name":"Department of Economics, Bo\u011fazi\u00e7i University","place":["Istanbul, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Rodchenko","sequence":"additional","affiliation":[{"name":"Columbia Data Analytics","place":["New York, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivanshu","family":"Awasthi","sequence":"additional","affiliation":[{"name":"Otsuka Pharmaceutical Development & Commercialization Inc.","place":["Princeton, NJ, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristine","family":"Harrsen","sequence":"additional","affiliation":[{"name":"H. Lundbeck A\/S","place":["Valby, Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"key":"B1","volume-title":"Diagnostic and Statistical Manual of Mental Disorders, 5th Edition, Text Revision","year":"2022"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1001\/archgenpsychiatry.2011.12","article-title":"Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative","volume":"68","author":"Merikangas","year":"2011","journal-title":"Arch Gen Psychiatry"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1590\/1516-4446-2012-1693","article-title":"Bipolar disorder prevalence: a systematic review and meta-analysis of the literature","volume":"37","author":"Clemente","year":"2015","journal-title":"Braz J Psychiatry"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychires.2016.10.003","article-title":"Epidemiology of DSM-5 bipolar I disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions - III","volume":"84","author":"Blanco","year":"2017","journal-title":"J Psychiatr Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2024.08.003","article-title":"A retrospective cross-sectional analysis of the humanistic and economic burden of bipolar I disorder","volume":"46","author":"Culpepper","year":"2024","journal-title":"Clin Ther"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/bdi.12584","article-title":"Assessment of cognitive functions in bipolar I disorder: a 1-year naturalistic follow-up study","volume":"20","author":"Sagar","year":"2018","journal-title":"Bipolar Disord"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2024.08.133","article-title":"Clinical characteristics and functioning of adults with bipolar I disorder: evidence from the mental and substance use disorders prevalence study","volume":"366","author":"Bareis","year":"2024","journal-title":"J Affect Disord"},{"key":"B8","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jad.2017.09.011","article-title":"The economic burden of bipolar I disorder in the United States in 2015","volume":"226","author":"Cloutier","year":"2018","journal-title":"J Affect Disord"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1176\/appi.focus.20230009","article-title":"The CANMAT and ISBD guidelines for the treatment of bipolar disorder: Summary and a 2023 update of evidence","volume":"21","author":"Keramatian","year":"2023","journal-title":"Focus (Am Psychiatr Publ)"},{"key":"B10","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/bdi.12609","article-title":"Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder","volume":"20","author":"Yatham","year":"2018","journal-title":"Bipolar Disord"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1177\/2045125318804364","article-title":"Medication nonadherence in bipolar disorder: a narrative review","volume":"8","author":"Jawad","year":"2018","journal-title":"Ther Adv Psychopharmacol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2147\/ppa.s39290","article-title":"Suboptimal treatment adherence in bipolar disorder: Impact on clinical outcomes and functioning","volume":"7","author":"Montes","year":"2013","journal-title":"Patient Prefer Adherence"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2023.04.030","article-title":"Non-adherence to mood stabilizers and antipsychotics among persons with bipolar disorder - a nationwide cohort study","volume":"333","author":"Lintunen","year":"2023","journal-title":"J Affect Disord"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2011.04.016","article-title":"Clinical and economic consequences of medication non-adherence in the treatment of patients with a manic\/mixed episode of bipolar disorder: results from the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM) study","volume":"190","author":"Hong","year":"2011","journal-title":"Psychiatry Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1097\/jom.0b013e3181db811d","article-title":"Indirect costs associated with nonadherence to treatment for bipolar disorder","volume":"52","author":"Bagalman","year":"2010","journal-title":"J Occup Environ Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1080\/13696998.2018.1543188","article-title":"Atypical antipsychotic adherence is associated with lower inpatient utilization and cost in bipolar I disorder","volume":"22","author":"Broder","year":"2019","journal-title":"J Med Econ"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.9740\/mhc.2022.10.270","article-title":"An update on recently approved long-acting injectable second-generation antipsychotics: knowns and unknowns regarding their use","volume":"12","author":"VandenBerg","year":"2022","journal-title":"Ment Health Clin"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-018-0785-y","article-title":"Medication adherence and discontinuation of aripiprazole once-monthly 400 mg (AOM 400) versus oral antipsychotics in patients with schizophrenia or bipolar I disorder: A real-world study using US claims data","volume":"35","author":"Yan","year":"2018","journal-title":"Adv Ther"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2017.1379412","article-title":"Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder","volume":"21","author":"Greene","year":"2018","journal-title":"J Med Econ"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1177\/07067437251412576","article-title":"Effectiveness of long-acting injectable antipsychotics versus oral antipsychotics in people with bipolar disorder: a systematic review and meta-analysis of observational studies | Efficacit\u00e9 des antipsychotiques injectables \u00e0 action prolong\u00e9e par rapport aux antipsychotiques oraux chez les personnes atteintes de troubles bipolaires : revue syst\u00e9matique et m\u00e9ta-analyse d'\u00e9tudes observationnelles","volume":"71","author":"Wagner","year":"2026","journal-title":"Can J Psychiatry"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2025.120989","article-title":"From crisis to control: The role of long-acting injectable antipsychotics in reducing psychiatric service use in bipolar disorder","volume":"397","author":"Kurt Tunagur","year":"2026","journal-title":"J Affect Disord"},{"key":"B22","unstructured":"Abilify Maintena\u00ae (aripiprazole). Prescribing information\n          \n          \n          \n          2026"},{"key":"B23","unstructured":"Abilify Asimtufii\u00ae (aripiprazole). Prescribing information\n          \n          \n          \n          2025"},{"key":"B24","article-title":"FDA approves Otsuka and Lundbeck\u2019s ABILIFY ASIMTUFII\u00ae (aripiprazole), the first once-every-two-months long-acting injectable (LAI) for the treatment of schizophrenia or maintenance monotherapy treatment of bipolar I disorder in adults [press release]","year":"2023"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-023-00996-8","article-title":"A randomized, open-label, multiple-dose, parallel-arm, pivotal study to evaluate the safety, tolerability, and pharmacokinetics of aripiprazole 2-month long-acting injectable in adults with schizophrenia or bipolar I disorder","volume":"37","author":"Harlin","year":"2023","journal-title":"CNS Drugs"},{"key":"B26","doi-asserted-by":"publisher","first-page":"20451253241278830","DOI":"10.1177\/20451253241278830","article-title":"Use of an injection of aripiprazole given once every 2\u2009months (Abilify Asimtufii\u00ae) in people with bipolar I disorder: a plain language summary of publication","volume":"14","author":"McIntyre","year":"2024","journal-title":"Ther Adv Psychopharmacol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2023.2219155","article-title":"Safety and efficacy of aripiprazole 2-month ready-to-use 960 mg: secondary analysis of outcomes in adult patients with bipolar I disorder in a randomized, open-label, parallel-arm, pivotal study","volume":"39","author":"McIntyre","year":"2023","journal-title":"Curr Med Res Opin"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/osp4.762","article-title":"Impact of semaglutide on osteoarthritis risk in patients with obesity: a retrospective cohort study","volume":"10","author":"Baser","year":"2024","journal-title":"Obes Sci Pract"},{"key":"B29","doi-asserted-by":"publisher","first-page":"44","DOI":"10.36469\/jheor.2023.87538","article-title":"Use of open claims vs closed claims in health outcomes research","volume":"10","author":"Baser","year":"2023","journal-title":"J Health Econ Outcomes Res"},{"key":"B30","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1056\/nejm200107123450205","article-title":"Neighborhood of residence and incidence of coronary heart disease","volume":"345","author":"Diez Roux","year":"2001","journal-title":"N Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/0895-4356(92)90016-g","article-title":"A chronic disease score from automated pharmacy data","volume":"45","author":"Von Korff","year":"1992","journal-title":"J Clin Epidemiol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/00005650-199801000-00004","article-title":"Comorbidity measures for use with administrative data","volume":"36","author":"Elixhauser","year":"1998","journal-title":"Med Care"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2008.01.006","article-title":"The Charlson comorbidity index is adapted to predict costs of chronic disease in primary care patients","volume":"61","author":"Charlson","year":"2008","journal-title":"J Clin Epidemiol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2003.09.002","article-title":"How to measure comorbidity. A critical review of available methods","volume":"56","author":"de Groot","year":"2003","journal-title":"J Clin Epidemiol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2014.20.7.756","article-title":"Methodological considerations in estimating adherence and persistence for a long-acting injectable medication","volume":"20","author":"Campagna","year":"2014","journal-title":"J Manag Care Spec Pharm"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.2147\/ppa.s410028","article-title":"Switching from monthly to three-monthly long-acting injectable paliperidone: a survey on subjective satisfaction and safety","volume":"17","author":"Barnett","year":"2023","journal-title":"Patient Prefer Adherence"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.2147\/ppa.s251812","article-title":"Patients' preference for long-acting injectable versus oral antipsychotics in schizophrenia: results from the patient-reported medication preference questionnaire","volume":"14","author":"Blackwood","year":"2020","journal-title":"Patient Prefer Adherence"},{"key":"B38","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1186\/s12888-021-03305-z","article-title":"The patient, investigator, nurse, carer questionnaire (PINC-Q): a cross-sectional, retrospective, non-interventional study exploring the impact of less frequent medication administration with paliperidone palmitate 3-monthly as maintenance treatment for schizophrenia","volume":"21","author":"Pungor","year":"2021","journal-title":"BMC Psychiatry"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1080\/08039488.2020.1841289","article-title":"Patients' perspectives on three-monthly administration of antipsychotic treatment with paliperidone palmitate - a qualitative interview study","volume":"75","author":"Rise","year":"2021","journal-title":"Nord J Psychiatry"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2025.2585558","article-title":"Understanding patient, caregiver, and prescriber preferences for an antipsychotic regimen administered once every 2 months for schizophrenia or bipolar I disorder: A qualitative interview study in North America","volume":"41","author":"McIntyre","year":"2025","journal-title":"Curr Med Res Opin"},{"key":"B41","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s40345-026-00414-0","article-title":"Views on an antipsychotic regimen administered once every 2 months: a qualitative interview study of people living with bipolar I disorder, caregivers, and prescribers in the USA and Canada","volume":"14","author":"Tohen","year":"2026","journal-title":"Int J Bipolar Disord"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.4088\/jcp.25m16154","article-title":"Outcomes and practice patterns of long-acting injectable versus oral antipsychotics among patients with bipolar I disorder in the United States: a hospital database analysis","volume":"87","author":"Kaplan","year":"2026","journal-title":"J Clin Psychiatry"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2017.4711","article-title":"Real-world effectiveness of pharmacologic treatments for the prevention of rehospitalization in a Finnish nationwide cohort of patients with bipolar disorder","volume":"75","author":"L\u00e4hteenvuo","year":"2018","journal-title":"JAMA Psychiatry"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2020.10.023","article-title":"Time to rehospitalization in patients with bipolar mania discharged on long-acting injectable or oral antipsychotics","volume":"279","author":"Lin","year":"2021","journal-title":"J Affect Disord"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2023.115676","article-title":"Impact of long-acting injectable antipsychotics vs. oral medication on relapses of patients with psychosis and bipolar disorder","volume":"332","author":"Vgontzas","year":"2024","journal-title":"Psychiatry Res"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2018.07.011","article-title":"Health care resource utilization and costs associated with transitioning to 3-month paliperidone palmitate among US veterans","volume":"40","author":"DerSarkissian","year":"2018","journal-title":"Clin Ther"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-019-01039-9","article-title":"Health outcomes among patients diagnosed with schizophrenia in the US Veterans Health Administration population who transitioned from once-monthly to once-every-3-month paliperidone palmitate: an observational retrospective analysis","volume":"36","author":"Patel","year":"2019","journal-title":"Adv Ther"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2025.2456014","article-title":"A review of clinical applications of pharmacokinetic simulations for a 2-month long-acting injectable formulation of aripiprazole","volume":"41","author":"Fagiolini","year":"2025","journal-title":"Curr Med Res Opin"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2025.31.1.60","article-title":"Budget impact of aripiprazole once every 2 months long-acting injectable for adult patients with bipolar I disorder in the United States","volume":"31","author":"Diaby","year":"2025","journal-title":"J Manag Care Spec Pharm"},{"key":"B50","doi-asserted-by":"publisher","first-page":"398","DOI":"10.4997\/jrcpe.2020.409","article-title":"Retrospective studies - utility and caveats","volume":"50","author":"Talari","year":"2020","journal-title":"J R Coll Physicians Edinb"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1007\/s40471-014-0027-z","article-title":"Misclassification in administrative claims data: quantifying the impact on treatment effect estimates","volume":"1","author":"Funk","year":"2014","journal-title":"Curr Epidemiol Rep"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1093\/bjs\/znaf139","article-title":"Potential for error when relying on administrative data","volume":"112","author":"Zelicha","year":"2025","journal-title":"Br J Surg"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-13-119","article-title":"Assessing regression to the mean effects in health care initiatives","volume":"13","author":"Linden","year":"2013","journal-title":"BMC Med Res Methodol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1258\/jrsm.2012.110319","article-title":"Disentangling secular trends and policy impacts in health studies: use of interrupted time series analysis","volume":"106","author":"Pape","year":"2013","journal-title":"J R Soc Med"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3390\/nu12072078","article-title":"The impact of a slow-release large neutral amino acids supplement on treatment adherence in adult patients with phenylketonuria","volume":"12","author":"Burlina","year":"2020","journal-title":"Nutrients"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/217047","article-title":"Medication adherence measures: an overview","volume":"2015","author":"Lam","year":"2015","journal-title":"BioMed Res Int"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1097\/mlr.0b013e31829b1d2a","article-title":"Standardizing terminology and definitions of medication adherence and persistence in research employing electronic databases","volume":"51","author":"Raebel","year":"2013","journal-title":"Med Care"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-024-01960-w","article-title":"Replicability and generalizability in population psychiatric neuroimaging","volume":"50","author":"Marek","year":"2024","journal-title":"Neuropsychopharmacology"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.36469\/001c.137909","article-title":"Open access to antipsychotics in state Medicaid programs: effect on healthcare resource utilization and costs among patients with serious mental illness","volume":"12","author":"Patel","year":"2025","journal-title":"J Health Econ Outcomes Res"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1904737\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T13:22:52Z","timestamp":1788873772000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2026.1904737\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":59,"alternative-id":["10.3389\/fpsyt.2026.1904737"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2026.1904737","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,8]]},"article-number":"1904737"}}